Gilles Litman, Former Vice President of Digital Health at Sanofi, Joins Remedee Labs to Accelerate Global Launch of Revolutionary Digital Health Platform Focused on Chronic Pain Management

Prior to joining Remedee Labs, Gilles was Vice President of Digital Health at Sanofi, where he worked on technology platforms focused on diabetes and cardiovascular disease. A graduate of ESSEC Paris, Gilles has more than 20 years of experience in the pharmaceutical industry, with distinguished expertise in strategy, international development and business management.

“The technological innovation and value proposition of Remedee Labs are unique and revolutionary in how they are changing the lives of patients with chronic pain. I am excited to join Remedee Labs to help accelerate product offerings and lead international expansion and business development. We have big goals at Remedee Labs, including our primary goal of making our services accessible to as many people with chronic pain as possible. “
Gilles Litman, Commercial Director, Remedee Labs

Changing the Lives of Chronic Pain Patients with Endorphin Stimulator and Digital Services Platform

Remedee Labs has developed a revolutionary, unique, non-invasive endorphin stimulation technology to improve the quality of life of patients with chronic pain.

Remedee Platform enables a complete and personalized experience with multidisciplinary care designed for both patients and practitioners. The platform enables remote assistance by care teams, coaches, practitioners and more, and includes personalized digital services available 24/7.

“Medication alone is often not enough to ease the burden on patients with chronic pain; holistic care and the combination of several approaches are essential. Remedee Platform responds to this need and improves the patient’s care path.
Teacher. Alain serrie, Head of pain and palliative medicine at AP-HP and founding president of Douleur Sans Frontière.

Useful for conditions without satisfactory treatment such as fibromyalgia and endometriosis, but also migraines and osteoarthritis

Fibromyalgia is a chronic, debilitating disease that affects many aspects of healthy living and quality of life. Treatment options are inconsistent in effectiveness, can be expensive, and often have unwanted side effects.

Technology developed by Remedee Labs to reduce stress and improve sleep has been shown to dramatically improve the quality of life of patients with fibromyalgia. In light of these promising results, Remedee Labs is launching a multicenter study on fibromyalgia and developing the first personalized support pathway for this condition.

“We will develop this platform with the help of patients with fibromyalgia, alongside a clinical trial we are launching in this condition using our personal endorphin stimulator – the only such technology in the world.”
David Crouzier, co-founder and CEO, Remedee Labs

In addition, Remedee Labs is expanding its range of services to treat other chronic pain issues and has launched several clinical trials in endometriosis, osteoarthritis, migraines, and cancer pain. The first data suggest a strong efficacy in the reduction of pain in various pathologies thanks to digitally stimulated endorphin pathways.

Global development potential

1.5 billion people worldwide suffer from chronic pain, 50% of whom have not found satisfactory treatment1 and the majority of whom say it affects their daily personal, social and professional life

“Gilles joined us at a key moment in the company’s history. His expertise will enable us to accelerate the development of our service platform for patients suffering from chronic pain and to begin our international expansion.”
Jacques Husser, co-founder and executive chairman, Remedee Labs

Remedee Labs raised 11 million euros nowadays. To support the company’s ambitions, new announcements are expected soon.

Endorphins stimulation using millimeter waves as an alternative for chronic pain management

Remedee Labs designed and developed the first endorphin stimulation solution, which transforms the management of chronic pain.

The result of many years of scientific research and solid partnerships (CEA-Leti, ST Microelectronics), this technology is based on the patented MEET (Microelectronic Endorphin Trigger) module, the first miniature module emitting millimeter waves. Embedded in a bracelet and placed inside the wrist, this module delivers an ultra-high frequency electronic signal that precisely stimulates the subcutaneous receptors (0.5 mm inside the skin).

In response to this painless nerve stimulation, the brain releases intracerebral endorphins which quickly relieve pain and also produce a feeling of well-being.

About Remedee Labs

1.5 billion people worldwide suffer from chronic pain and more than half of them are not satisfied with their care. Remedee Labs aims to breathe new life into these patients.

Based on 10 years of preclinical and clinical research, Remedee Labs has developed the first endorphin stimulator for personal use. Building on the experience of its clinical partners, the company now uses its unique technology to deliver the first patient-centric digital service platform for chronic pain management, in collaboration with physicians. The initial goal of Remedee Labs is to help fibromyalgia patients and plans to expand the platform’s offering to other chronic pain issues in the near future.

Founded in 2016, Remedee Labs announced in 2019 that it had raised 11 million euros investors, including HCVC, Habert Dassault Finance, Partech, Supernova Invest and Company C4.


Remedee Laboratories, Quentin Richard, +33 (0) 7 67 17 01 91, [email protected]
PRPA Agency, Damien Maillard, [email protected]

Photo –
Logo –

SOURCE Remedee Labs

Source link

More Stories
What will he bet on beyond subscriptions? – The Hollywood journalist